Active ingredientAbeprazanCat. No. P-A004-001CAS 1902954-60-2Family · Pharmaceutical analytical standards
Abeprazan
A potassium-competitive acid blocker (P-CAB), also known as fexuprazan, developed in South Korea: it has been approved there and in other countries, including Mexico, the Philippines, Chile and Ecuador, for gastro-oesophageal reflux disease. This family brings together the active ingredient and other impurities.
Did you know?The suffix -prazan sets this new class apart from the classic proton pump inhibitors ending in -prazole: unlike them, it does not need the acidic stomach environment to become active.
Go to the active ingredient →Active ingredientAbeprazanCat. No. P-A004-001CAS 1902954-60-2
Active ingredientAbeprazan HClCat. No. P-A004-002CAS 1902954-87-3
ImpurityAbeprazan 3-chloro Impurity HCl SaltCat. No. P-A004-005
ImpurityAbeprazan DimerCat. No. P-A004-006
ImpurityAbeprazan Impurity 1Cat. No. P-A004-007No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.